廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,041.17
    +30.50 (+1.01%)
     
  • 滬深300

    3,537.48
    +16.52 (+0.47%)
     
  • 美元

    7.8259
    +0.0003 (+0.00%)
     
  • 人民幣

    0.9220
    -0.0008 (-0.09%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0515
    +0.0000 (+0.08%)
     
  • 歐元

    8.4508
    +0.0102 (+0.12%)
     
  • 英鎊

    9.8860
    +0.0100 (+0.10%)
     
  • 紐約期油

    83.11
    -0.06 (-0.07%)
     
  • 金價

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin

    70,221.38
    -396.70 (-0.56%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

FDA Approves Insulet's Omnipod Automated Insulin System For Patients Two Years & Above

  • The FDA has cleared Insulet Corporation's (NASDAQ: PODD) Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes (T1D).

  • Omnipod 5 is tubeless automated insulin delivery (AID) system in the U.S. that was initially cleared for use in individuals aged six and older in January 2022.

  • Also Read: Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance.

  • In a recent publication by Sherr et al. in Diabetes Care, Omnipod 5 significantly improved time in range and reduced HbA1c and time in hypoglycemia (<70 mg/dL) in very young children (aged 2 – 5.9 years) with type 1 diabetes.

  • Related: Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes.

  • Healthcare professionals can now prescribe Omnipod 5 to their patients with insurance coverage. Patients can access their prescription through the pharmacy channel, meaning there is no contract or commitment.

  • Price Action: PODD shares closed at $267.42 on Friday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.